Seed DS-01

• Daily microbiome and digestive support (Seed's primary positioning)
• Bloating, abdominal discomfort and bowel regularity (Seed-funded 2026 trial, self-reported outcomes)
• Support after a course of antibiotics (rests largely on single-strain LGG evidence, not the finished blend)
• Increasing urolithin A and butyrate production (Seed-funded DDW 2025 data)
• Gut-skin support (early Seed pilot, preliminary)

Seed DS-01 is the foundational Daily Synbiotic from Seed Health, the direct-to-consumer microbiome company founded in 2017 by Ara Katz and Raja Dhir. The product is positioned as a 2-capsule daily probiotic-plus-prebiotic combination (the technical "synbiotic" designation reflecting integrated probiotic and prebiotic supplementation rather than either alone). The formulation provides 24 clinically-studied probiotic strains across multiple genera and species (predominantly Lactobacillus, Bifidobacterium, and Lactococcus species; specific strain-level identifiers disclosed publicly through Seed's substantial transparency framework) at a total guaranteed potency of 53.6 billion AFU (Active Fluorescent Units, Seed's measurement framework distinct from traditional CFU counting that emphasizes viable cells rather than total cell counts). The prebiotic component includes microbiota-accessible carbohydrates and Indian pomegranate punicalagin (a polyphenol with substantial preclinical microbiome interaction evidence). The ViaCap delivery technology uses capsule-in-capsule construction, the outer capsule designed for gastric protection, the inner capsule containing the probiotic-prebiotic combination, supporting bacterial viability through stomach acid passage to intestinal target sites. The substantial 2-capsule daily dosing format contrasts with the powder formats of greens-category products (AG1, Bloom, Huel Daily Greens, Live It Up), Seed DS-01 is in the same Class C (single-brand multi-ingredient) category structurally but with substantially different commercial positioning, ingredient composition, and clinical evidence framework. The pharmacological mechanism profile centers on substantial probiotic strain-specific biology rather than general nutritional supplementation. The probiotic component supports gut microbiome composition through bacterial colonization (transient rather than permanent in most cases, most probiotic effects persist only during active supplementation), competitive exclusion of pathogenic bacteria, short-chain fatty acid (SCFA) production through bacterial fermentation, modulation of intestinal barrier function (tight junction integrity, mucin production), immunomodulation through Peyer's patches and intestinal immune signaling, neurotransmitter precursor production (serotonin, GABA, others through gut-brain axis signaling), and modulation of metabolic markers through bile acid metabolism and broader microbiome biochemistry. The prebiotic polyphenols (punicalagin from Indian pomegranate) provide substrate for beneficial bacteria and possible direct epithelial effects. The substantial M-10 Strain-Specificity flag relevance, the probiotic effects are substantially strain-specific rather than genus- or species-specific. Lactobacillus rhamnosus GG (LGG) effects do not generalize to all L. rhamnosus strains; Bifidobacterium animalis subsp. lactis BB-12 effects do not generalize to all B. lactis strains. Seed DS-01's 24-strain composition includes substantial clinically-studied strains across multiple application categories (gut health, immune support, dermatological applications, cardiovascular markers, others). The Seed Health commercial framework represents distinct positioning from greens-category Class C products. The substantial scientific advisory framework includes Jacques Ravel (University of Maryland Institute for Genome Sciences microbiome research leader), Greg Gloor (Western University bioinformatics microbiome research), various microbiome researchers. The substantial transparency emphasis (publishing detailed strain identifiers, mechanism citations, third-party verification) contrasts with substantial proprietary blend opacity in many supplement category competitors. The B Corp certification (substantial corporate sustainability commitment), the substantial direct-to-consumer subscription model ($49.99/month with refillable glass jar starter framework), and the substantial editorial content investment (Seed produces substantial original microbiome science content through their platform) reflect substantial brand positioning emphasizing scientific rigor and consumer education. The substantial commercial framework emerged from Ara Katz's background in marketing strategy and content (Spring Studios, Lyst, others) and Raja Dhir's background in microbiome science and bioengineering, the substantial founder framework integrates substantial commercial strategy with substantial scientific framework. The substantial Series B and Series C funding rounds (2021, 2023) reflect substantial venture capital validation; specific valuation and acquisition possibilities continue to evolve. The clinical evidence framework distinguishes Seed DS-01 from substantial greens-category competitors. The substantial strain-level clinical evidence inheritance, each of the 24 strains has substantial published clinical research investment from various manufacturers and academic researchers, provides foundational pharmacological credibility distinct from brand-specific clinical trial investment (which Seed DS-01 has limited). The substantial scientific advisory framework supports the strain selection process; the substantial transparency framework allows consumers to verify strain identifiers against published research. The combination provides substantial multi-strain probiotic supplementation framework distinct from single-strain dedicated probiotic products (Lactobacillus rhamnosus GG, Bifidobacterium animalis BB-12, etc.) and substantial multi-strain probiotic alternatives (Visbiome, VSL#3, others). The substantial daily synbiotic positioning emphasizes integrated probiotic-prebiotic supplementation framework rather than either alone.

Seed DS-01 is dosed at 2 capsules daily, ideally taken first thing in the morning on an empty stomach with water for optimal gastric transit. The substantial 53.6 billion AFU total potency across 24 strains provides multi-strain probiotic supplementation framework distinct from single-strain probiotic alternatives. Take the capsules consistently, daily probiotic supplementation works through sustained microbiome influence rather than acute pharmacological effect; missing doses occasionally is unlikely to substantially affect outcomes, but sustained daily use over 1-3+ months allows microbiome assessment. The substantial subscription model ($49.99/month) supports sustained daily use through automatic monthly delivery framework. Storage: room temperature is acceptable through the ViaCap technology stability; refrigeration is not required but may extend shelf life modestly. The substantial glass jar refillable framework provides sustainability positioning; monthly refill pouches replace the jar contents. The substantial 2-capsule format contrasts with greens-category powder products (AG1, Bloom, Huel Daily Greens, Live It Up), Seed DS-01 is a dedicated probiotic synbiotic rather than a multi-ingredient greens powder. Substantial complementary supplementation framework: Seed DS-01 for dedicated probiotic supplementation; greens powder for multi-ingredient nutritional bridge; standalone targeted supplementation for specific therapeutic dose individual nutrients. Treatment durations matter substantially, probiotic effects typically develop over 4-12 weeks of consistent supplementation; some applications (post-antibiotic microbiome restoration) may benefit from 1-3 month courses. The substantial transparency framework allows consumers to verify specific strain identifiers (DSM, ATCC, CECT numerical designators) against published clinical research for specific applications. The clinical evidence base for Seed DS-01 specifically is limited (Yang 2022 J Drugs Dermatol dermatological pilot is among the brand-specific clinical investments); strain-level clinical evidence inheritance provides substantial pharmacological credibility for individual constituents. The drug interaction profile is modest for most users, live probiotics generally do not produce substantial drug interactions; immunosuppressed users warrant specialist coordination given theoretical bacteremia risk. Pregnancy and lactation: probiotic supplementation generally considered safe; coordinate with OB-GYN. Pediatric use: Seed PDS-08 Pediatric Daily Synbiotic is the appropriate pediatric formulation; adult DS-01 not appropriate for pediatric supplementation. The substantial scientific advisory framework (Jacques Ravel UMD, Greg Gloor Western, others) provides substantial brand credibility distinct from substantial supplement category proprietary blend opacity. The substantial 30-day money-back guarantee provides reasonable consumer trial framework.

Standard daily dose

2 capsules daily

Timing

First thing in morning on empty stomach

Total probiotic potency

53.6 billion AFU across 24 strains

Pediatric formulation

Seed PDS-08 (ages 3-17)

Storage

Room temperature acceptable (no refrigeration required)

Subscription pricing

$49.99/month (DTC subscription)

Treatment duration for chronic effects

4-12+ weeks

Post-antibiotic course

1-3 months post-antibiotic restoration

• Seed DS-01 Daily Synbiotic (Adult)

  Rating: gold

  The flagship Seed DS-01 adult formulation, 2-capsule daily synbiotic with 24 probiotic strains (53.6 billion AFU total) and prebiotic polyphenols (Indian pomegranate punicalagin and microbiota-accessible carbohydrates). ViaCap delivery technology. Glass refillable jar starter and monthly subscription pouch refills. $49.99/month subscription model.

• Seed PDS-08 Pediatric Daily Synbiotic

  Rating: gold

  Pediatric Seed Daily Synbiotic formulation, specifically formulated for children ages 3-17. Different strain composition appropriate for pediatric microbiome. Substantial pediatric product expansion launched 2023. Reasonable pediatric synbiotic option under pediatrician coordination.

• Seed Subscription Direct-to-Consumer Model

  Rating: gold

  Direct-to-consumer subscription framework, $49.99/month for monthly delivery with substantial subscription discount versus one-time purchase. Substantial brand engagement infrastructure through subscription model. Travel-friendly refillable glass jar starter with monthly refill pouch shipment.

• Seed Travel Glass Jar Refill Format

  Rating: gold

  Substantial sustainability positioning through reusable glass jar storage with monthly refill pouches, substantially less packaging waste than typical supplement plastic bottle distribution. Reasonable consumer choice for users prioritizing sustainability framework.

• Seed Health Microbiome Editorial Content

  Rating: good

  Substantial original microbiome science editorial content through Seed's content platform (sustainability, microbiome science, consumer education). The substantial editorial investment provides substantial brand engagement and consumer education framework distinct from purely commercial supplement marketing.

• Dedicated Single-Strain Probiotic Alternatives

  Rating: good

  For users seeking specific therapeutic strain effects (LGG for diarrhea prevention, Bifidobacterium longum 35624 for IBS, Bifidobacterium animalis BB-12 for immune, Lactobacillus reuteri DSM 17938 for infant colic, others), dedicated single-strain products provide substantial therapeutic single-strain dosing. Reasonable alternative or complement to multi-strain synbiotic supplementation.

• Multi-Strain Pharmaceutical Probiotic Alternatives

  Rating: gold

  Visbiome (formerly VSL#3, substantial pharmaceutical-grade multi-strain probiotic with 450 billion CFU per packet) provides substantial pharmaceutical-grade multi-strain alternative for users seeking pharmaceutical-grade ulcerative colitis and pouchitis applications. Reasonable alternative for users with documented inflammatory bowel disease requiring pharmaceutical-grade probiotic intervention.

• AG1, Bloom, Huel, Live It Up Greens Powder Probiotic Components

  Rating: caution

  The probiotic components within greens powder products (AG1, Bloom, Huel Daily Greens, Live It Up) are substantially modest doses relative to dedicated probiotic products. Users seeking substantial probiotic supplementation should consider dedicated probiotic products (Seed DS-01, single-strain alternatives, pharmaceutical-grade alternatives) rather than relying on greens powder probiotic content.

• Adults seeking daily microbiome supplementation

  Strength of evidence for this group: modest

  Seed DS-01 provides substantial 24-strain synbiotic supplementation framework for adults seeking daily microbiome support. Effect sizes consistently modest; reasonable daily supplementation framework. The substantial 2-capsule daily format provides reasonable convenience.

• IBS and functional GI disorders (adjunctive)

  Strength of evidence for this group: cautious

  The Bifidobacterium longum 35624 strain in Seed DS-01 has substantial IBS clinical evidence (Whorwell 2006 foundational); other strains provide additional functional GI support. Modest effect sizes; reasonable adjunct to comprehensive IBS management. Coordinate with gastroenterology for established functional GI disease.

• Post-antibiotic microbiome restoration

  Strength of evidence for this group: modest

  Post-antibiotic microbiome disruption is substantial; multi-strain probiotic supplementation supports microbiome restoration. The substantial 24-strain composition provides reasonable framework for diverse microbiome reseeding. Start during antibiotic course (separated 2-3 hours from antibiotic dose) and continue 1-3 months post-antibiotic for sustained microbiome restoration.

• Travel and gastroenteritis prevention

  Strength of evidence for this group: cautious

  Lactobacillus rhamnosus GG and similar substantial probiotic strains have substantial evidence for travelers' diarrhea prevention. Seed DS-01's multi-strain composition provides reasonable framework for travel supplementation. Initiate 1-2 weeks before travel; continue during and 1-2 weeks after.

• Inflammatory and dermatological applications (preliminary)

  Strength of evidence for this group: cautious

  Yang 2022 J Drugs Dermatol Seed DS-01 dermatological pilot trial showed modest acne improvement evidence. Substantial preliminary evidence for gut-skin axis applications. Reasonable adjunct to comprehensive dermatology management.

• Pregnancy and lactation

  Strength of evidence for this group: cautious

  Multi-strain probiotic supplementation generally safe during pregnancy; specific Seed DS-01 pregnancy safety data limited. Coordinate with OB-GYN; specific probiotic strains (Lactobacillus rhamnosus GG particularly) have substantial pregnancy and infant evidence base.

• Pediatric use (PDS-08 specific formulation)

  Strength of evidence for this group: modest

  Seed PDS-08 Pediatric Daily Synbiotic is specifically formulated for children ages 3-17. Adult DS-01 formulation not appropriate for pediatric supplementation. Pediatrician coordination essential.

• Immunocompromised users (caution)

  Strength of evidence for this group: cautious

  Live probiotic supplementation carries theoretical risk in severely immunocompromised users (active chemotherapy, severe immunodeficiency, central venous catheter users); documented but rare bacteremia case reports with various probiotic products. Specialist immunology coordination essential for immunocompromised contexts; benefit-risk assessment matters substantially.

• Healthy adults (preventive supplementation)

  Strength of evidence for this group: modest

  Most healthy adults can achieve modest microbiome support through dietary fiber, fermented foods (yogurt, kefir, kimchi, sauerkraut, kombucha), and diverse whole-foods diet. Probiotic supplementation provides additional support framework; not substitute for dietary microbiome support. Reasonable supplementation for users prioritizing comprehensive microbiome approach.

• Established inflammatory bowel disease (UC, Crohn's)

  Strength of evidence for this group: cautious

  Established UC and Crohn's disease management may benefit from probiotic supplementation; pharmaceutical-grade alternatives (Visbiome for pouchitis and UC specifically) have substantial pharmaceutical inheritance versus Seed DS-01 consumer supplement positioning. Coordinate with gastroenterology; pharmaceutical-grade options may be preferred for established IBD.

• Severe lactose intolerance

  Strength of evidence for this group: modest

  Some strains (particularly Bifidobacterium and Lactobacillus species) support lactose metabolism. Modest evidence for lactose intolerance support. Reasonable adjunct to comprehensive lactose intolerance management.

• C. difficile prevention (post-antibiotic)

  Strength of evidence for this group: cautious

  Some probiotic strains (Saccharomyces boulardii particularly) have substantial C. difficile prevention evidence in high-risk hospitalized patients. Seed DS-01 does not include S. boulardii; for specific C. difficile prevention applications, dedicated S. boulardii products (Florastor) provide more targeted intervention.

• Greens Powder (AG1, Bloom, Huel, Live It Up)

  Interaction: synergy

  Complementary positioning, Seed DS-01 for dedicated probiotic supplementation framework; greens powder for multi-ingredient nutritional bridge. The greens powders include modest probiotic content (substantially below Seed DS-01's 53.6 billion AFU therapeutic range) and substantial fiber/prebiotic content. Reasonable comprehensive framework using Seed DS-01 for probiotic + greens powder for multi-nutrient nutritional bridge.

• Dietary Fiber and Fermented Foods

  Interaction: synergy

  Substantial complementary positioning, dietary fiber (vegetables, legumes, whole grains) provides prebiotic substrate; fermented foods (yogurt, kefir, kimchi, sauerkraut, kombucha) provide additional probiotic supplementation. Reasonable comprehensive microbiome support combining Seed DS-01 with substantial dietary fiber and fermented food intake.

• Standalone Targeted Supplementation

  Interaction: synergy

  For users seeking specific therapeutic dosing of individual nutrients (vitamin D3, magnesium, omega-3, etc.), standalone targeted supplementation provides substantially better dose precision than relying on multi-ingredient probiotic/greens powder framework. Reasonable combination of Seed DS-01 for dedicated probiotic + standalone supplementation for specific therapeutic dosing.

• Dedicated Single-Strain Probiotics

  Interaction: synergy

  For users seeking specific therapeutic strain effects (LGG for diarrhea, BB-12 for immune, longum 35624 for IBS, reuteri DSM 17938 for infant colic, others), dedicated single-strain products provide therapeutic single-strain dosing complementary to or instead of multi-strain Seed DS-01 supplementation. Reasonable choice based on specific therapeutic application.

• Saccharomyces boulardii (Florastor)

  Interaction: synergy

  S. boulardii provides distinct yeast-based probiotic pharmacology complementary to bacterial probiotic supplementation. For users seeking specific C. difficile prevention or antibiotic-associated diarrhea applications, S. boulardii provides targeted intervention. Reasonable addition to Seed DS-01 for specific applications.

• Antibiotics (During Course)

  Interaction: caution

  Probiotic supplementation during antibiotic course should be separated by 2-3 hours from antibiotic dose to support probiotic viability. The substantial probiotic-antibiotic timing matters for therapeutic effect; some probiotic strains (Saccharomyces boulardii particularly) have substantial evidence for antibiotic-associated diarrhea prevention.

• Immunosuppressants

  Interaction: caution

  Live probiotic supplementation in severely immunocompromised users (active chemotherapy, severe immunodeficiency, central venous catheter users) carries theoretical bacteremia risk. Coordinate with immunology specialist; benefit-risk assessment essential for immunocompromised contexts.

• Anticoagulants

  Interaction: caution

  Some probiotic strains may modestly produce vitamin K2 (menaquinone) through bacterial metabolism, theoretical warfarin interaction. Generally well-tolerated at typical probiotic doses; monitor INR if substantial probiotic supplementation initiated in warfarin users.

• Pregnancy and Lactation

  Interaction: synergy

  Probiotic supplementation during pregnancy is generally considered safe and may provide modest infant outcomes benefits (eczema prevention, immune development). Coordinate with OB-GYN; specific strain selection (LGG particularly) may have substantial pregnancy and infant evidence base.

• Pediatric Use (PDS-08)

  Interaction: synergy

  Seed PDS-08 Pediatric Daily Synbiotic is specifically formulated for ages 3-17. Adult DS-01 not appropriate for pediatric supplementation. Reasonable pediatric microbiome support under pediatrician coordination.

• Other Multi-Ingredient Probiotic Products

  Interaction: caution

  Combining Seed DS-01 with other multi-strain probiotic products (Visbiome, Florastor, others) produces substantial strain duplication without proportional benefit. Reasonable choice between probiotic products rather than combination supplementation.

• Established Inflammatory Bowel Disease (UC, Crohn's)

  Interaction: caution

  For established UC and Crohn's disease management, pharmaceutical-grade probiotic alternatives (Visbiome for pouchitis and UC) may be preferred over consumer supplement positioning. Coordinate with gastroenterology.

Look for: explicit strain identifier disclosure (DSM, ATCC, CECT numerical designators allowing verification against published clinical research); explicit AFU or CFU content per serving disclosed; appropriate dose for intended use (53.6 billion AFU is reasonable multi-strain dose); substantial scientific advisory framework verification; substantial transparency framework verification; B Corp certification for sustainability framework; reputable manufacturer with quality control disclosure. Avoid: probiotic products without specific strain identifier disclosure; proprietary blends without per-strain potency disclosure; aggressive marketing claims about specific clinical outcomes that exceed brand-specific evidence base; very low-cost probiotic alternatives that may not maintain probiotic viability through manufacturing and storage; products from manufacturers without third-party testing or transparency framework disclosure.

Seed Health was founded in 2017 by Ara Katz and Raja Dhir in Los Angeles with substantial vision for science-driven consumer microbiome supplementation. Ara Katz brought substantial background in marketing strategy and content (Spring Studios CMO, Lyst, BeachMint co-founder, and various other media/wellness entrepreneurship). Raja Dhir brought substantial background in microbiome science and bioengineering. The substantial founder framework integrated substantial commercial strategy with substantial scientific framework. The initial Seed DS-01 Daily Synbiotic product launch occurred 2018-2019 with substantial transparency framework, substantial scientific advisory positioning, and substantial DTC subscription model. The substantial founding scientific advisors included Jacques Ravel (University of Maryland Institute for Genome Sciences, substantial microbiome research leader), Greg Gloor (Western University, microbiome bioinformatics research), and various other substantial microbiome researchers. The substantial scientific advisory framework provided substantial brand credibility distinct from substantial supplement category positioning that lacks academic scientific advisory framework. The substantial commercial growth era developed substantially through 2019-2024. The substantial Series A funding round (2018-2019) provided foundational investment; Series B in 2021 ($40 million) supported substantial commercial expansion; Series C in 2023 supported continued growth. The substantial venture capital validation reflects substantial investor interest in the microbiome supplementation category. The substantial product expansion era added Seed PDS-08 Pediatric Daily Synbiotic in 2023, substantial pediatric microbiome supplementation framework. The substantial editorial content investment through Seed's content platform produced substantial original microbiome science content (sustainability framework, microbiome science explainers, consumer education content) providing substantial brand engagement distinct from purely commercial supplement marketing. The substantial B Corp certification (2020) reflected substantial corporate sustainability commitment. The substantial glass jar refillable framework with monthly refill pouch shipments provided distinctive sustainability positioning in the supplement category. The substantial brand-specific clinical research investment has included Yang 2022 J Drugs Dermatol dermatological pilot trial demonstrating modest acne improvement evidence. The substantial brand-specific clinical evidence base is more limited than the substantial strain-level clinical evidence inheritance, Seed DS-01 relies substantially on substantial strain-specific clinical research investment from various manufacturers and academic researchers rather than substantial brand-specific clinical trial investment (which Seed has limited investment historically). The substantial regulatory framework includes FDA scrutiny of probiotic claims (the substantial FDA and FTC scrutiny of supplement marketing claims affects the broader probiotic category) and substantial DTC subscription model regulatory compliance. The substantial competitive context within the Class C single-brand multi-ingredient category includes substantial AG1 (Athletic Greens, 75+ ingredient greens powder, $79+/month, substantial third-party testing investment), Bloom (Bloom Nutrition Greens & Superfoods, ~30 ingredient greens powder, $30-40/month, substantial influencer marketing, 2024 Nestlé Health Science acquisition), Huel Daily Greens (UK-based, 91-ingredient greens powder, plant-based positioning, $50-70/month, 2023 launch), Live It Up Daily Greens (newer entrant, ~20 ingredient greens powder, $30-50/month, plant-based positioning). The substantial Seed DS-01 positioning as dedicated probiotic synbiotic provides distinct category positioning within the broader Class C framework. The modern consumer market has expanded substantially through the 2020s with Seed DS-01 emerging as among the most-prominent science-positioning probiotic supplements globally. The substantial transparency framework, substantial scientific advisory positioning, substantial sustainability emphasis, and substantial DTC subscription model distinguish Seed from substantial supplement category competitors. The continued evolution of microbiome science continues to shape the broader category framework.

1. 2017Seed Health founded by Ara Katz and Raja Dhir in Los Angeles
2. 2018-2019Seed DS-01 Daily Synbiotic initial product launch
3. 2018-2019Series A venture capital funding
4. 2020B Corp certification; substantial sustainability framework
5. 2021Series B funding round ($40 million)
6. 2022Yang J Drugs Dermatol dermatological pilot trial
7. 2023Seed PDS-08 Pediatric Daily Synbiotic launch; Series C funding
8. 2023-2024Continued commercial expansion and editorial content investment
9. 2020sEstablished Class C category positioning vs greens powder competitors

• Whether the substantial 24-strain composition produces clinically meaningful advantages over targeted single-strain or smaller multi-strain alternatives in specific applications, substantial strain breadth vs strain-specific therapeutic positioning.
• Whether brand-specific clinical evidence will mature substantially for Seed DS-01 beyond Yang 2022 dermatology pilot and strain-level evidence inheritance.
• Whether the substantial AFU measurement framework will gain broader industry adoption versus traditional CFU framework, measurement standardization across the probiotic category remains substantial methodology consideration.
• Whether the substantial DTC subscription model will sustain or face mass-market retail competitive pressure (the substantial Bloom mass-market retail expansion model contrasts with Seed's DTC focus).
• Whether the substantial scientific advisory framework (Jacques Ravel UMD, Greg Gloor Western, others) translates to substantial product positioning or remains substantial brand credibility framework.
• How best to position Seed DS-01 within the broader Class C single-brand multi-ingredient category, substantial probiotic-specific framework versus broader greens-category competitors.
• Whether the substantial polyphenol-prebiotic synbiotic positioning (Indian pomegranate punicalagin and microbiota-accessible carbohydrates) produces clinically meaningful advantages versus probiotic-only supplementation.
• Whether genetic variants affecting microbiome composition produce individual variability in Seed DS-01 clinical response.
• How the substantial regulatory scrutiny of probiotic claims (FDA, FTC) affects Seed DS-01 marketing positioning over time.
• Whether the substantial ViaCap delivery technology produces clinically meaningful advantages versus standard enteric-coated probiotic capsule alternatives.

Direct-to-consumer through Seed Health (seed.com) with substantial monthly subscription model ($49.99/month). Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. The substantial DTC subscription model contrasts with mass-market retail expansion of competitors (Bloom Target/Walmart expansion). Seed has expanded select retail through specialty retailers and selected health/wellness channels but maintains substantial DTC focus. International availability includes US, Canada, and select international markets through Seed shipping framework. Pricing: $49.99/month subscription provides 60-capsule monthly delivery (2 capsules daily x 30 days); one-time purchase pricing modestly higher. The substantial 30-day money-back guarantee provides reasonable consumer trial framework. The substantial glass refillable jar starter framework with monthly refill pouch shipment provides distinctive sustainability positioning. The substantial Series B and Series C venture capital funding has supported substantial brand development and clinical research investment. The substantial scientific advisory framework (Jacques Ravel, Greg Gloor, others) supports substantial brand credibility. Production sourcing involves specialty probiotic strain suppliers including Chr. Hansen, DuPont/IFF/Danisco, Lallemand, and other established probiotic manufacturers. Specific strain identifiers (DSM, ATCC, CECT numerical designators) are published through Seed's transparency framework allowing consumer verification against published clinical research. Manufacturing involves substantial quality control with substantial third-party testing investment. The substantial editorial content investment through Seed's content platform provides substantial consumer education framework distinct from purely commercial supplement marketing. The substantial B Corp certification reflects substantial corporate sustainability commitment.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Class

Single-brand multi-strain probiotic synbiotic

Brand

Seed Health (founded 2017)

Founders

Ara Katz and Raja Dhir

Product launch

2018-2019

Format

2 capsules daily (ViaCap capsule-in-capsule)

Probiotic strains

24 strains across Lactobacillus, Bifidobacterium, Lactococcus genera

What follows is unfinished work on our side, not a finding about Seed DS-01. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.